CA
RMD icon

Cullinan Associates’s ResMed RMD Stock Holding History

Cullinan Associates’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,000
Closed -$229K – 224
2024
Q4 		$229K Hold
1,000
– – 0.01% 210
2024
Q3 		$240K Sell
1,000
-2,000
-67% -$447K 0.01% 220
2024
Q2 		$574K Sell
3,000
-1,000
-25% -$203K 0.03% 175
2024
Q1 		$792K Sell
4,000
-2,300
-37% -$421K 0.04% 169
2023
Q4 		$1.08M Sell
6,300
-800
-11% -$123K 0.06% 140
2023
Q3 		$1.05M Sell
7,100
-2,400
-25% -$434K 0.06% 141
2023
Q2 		$2.08M Buy
+9,500
New +$2.12M 0.11% 120
2022
Q1 		– Sell
-800
Closed -$208K – 243
2021
Q4 		$208K Buy
+800
New +$208K 0.01% 227

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Cullinan Associates's RMD Position: Q1 2025 in Review

Cullinan Associates sold out of ResMed (RMD) in Q1 2025, closing a stake of 1,000 shares — an estimated $229K sold.

Cullinan Associates first reported a position in RMD in Q4 2021 and held it in 8 quarters. The position peaked at $2.08M in Q2 2023. 885 funds tracked by Wall St. Rank hold RMD as of Q1 2025.

  • Cullinan Associates reported no remaining ResMed position as of Q1 2025 after selling out during the quarter.
  • Cullinan Associates sold 1,000 ResMed shares in Q1 2025, an estimated $229K.
  • Cullinan Associates first reported a position in ResMed in Q4 2021 and held it in 8 quarters.
  • Cullinan Associates's ResMed position peaked at $2.08M in Q2 2023.
  • 885 funds tracked by Wall St. Rank held ResMed as of Q1 2025.

Based on Cullinan Associates's 13F filing for Q1 2025, filed 22 Apr 2025.